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neurocognitive disorders in late life, either through impaired brain development or
adverse metabolic programming.
Methods: Systematic review of literature investigating the relationship between
size at birth and cognitive abilities in late life. The search, data extraction, and rating
for the quality of reporting were conducted independently by two researchers.
Results: Of 533 selected studies, 11 were included in this systematic review and 10
of these were from high‐income setting. Of these 11 studies, eight indicated that
lower birth weight is a risk factor for lower cognitive function in late life, at least in
high‐income countries. The reported effect sizes were small and it was not possible
to conduct meta‐analyses because of clinical heterogeneity
Discussion: A modest association of lower birth weight with lower cognitive
abilities in late life is consistent with persisting effects of the prenatal environment
on brain function. As with all observational studies, confounding is an alternative
explanation. Further studies are required to elucidate the mechanisms.
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Key points
Recent evidence suggests that growth restriction in utero
may lead to neurocognitive disorders in later life, either
through impaired brain development or adverse metabolic
programming. A modest association of lower birth weight
with lower cognitive abilities in later life, observed in this
systematic review, is consistent with persisting effects of
the prenatal environment on brain function in later life.
1140 KRISHNA ET AL.hypothesis with two plausible pathways to cognitive ageing: (a) by a
direct effect of reduced intrauterine nutrition (reflected in birth size)
on fetal brain development leading to reduced cognitive reserve and
decreased cognitive ability or (b) programming of metabolism in very
early life by under‐nutrition, leading to increased risk mediated
through cardiometabolic disorders.3
Quality of nutrition during intrauterine development, reflected
crudely in size at birth, is an important determinant of lifelong func-
tion, health, and disease risk.4 Birth weight and head circumference
at birth are indicators of intrauterine growth and brain development,
respectively.5 Larger birth weight, the most widely researched birth
size measure, is associated with better cognitive function and higher
intelligence from infancy through the third decade of life in several
populations and countries independent of social background.6-8 This
association of birth weight with cognition occurs across the whole
spectrum of birth weight rather than being confined to an extreme
group. However, the strength of this association is known to diminish
as individuals reach middle age, and associations with growth in early
life may not persist beyond midlife.8
In a systematic review conducted in 2015, Grove and colleagues
examined the relationship between birth weight and general cognitive
ability in non‐clinical adult populations.8 This included 1 122 858 par-
ticipants aged between 18 to 78.4 years from 19 studies. Of these,
only eight could be included in a random‐effects meta‐analysis and
three were in those aged 60 yrs and above. There was a modest asso-
ciation of birth weight with cognitive ability; with each kilogramme
increase in birth weight, there was a 0.13 SD increase in general intel-
ligence (95% CI, 0.07,‐0.19) in those aged less than 60 yrs, indepen-
dent of gestational age and parental social class at birth. However,
the effect size was much lower and not statistically significant in those
aged 60 years and above (0.07 SD; 95% CI, −0.02 to 0.16). In addition
to the small number of studies, the authors did not consider other
birth size parameters (like head circumference, length at birth, and
ponderal index), which are known to be associated with cognitive
ability in this age group.9-11 While birth weight was not a reliable pre-
dictor of cognitive ability or decline beyond midlife in this review, it
would be premature to conclude that prenatal environment is not
associated with cognitive ability in late life.2 | AIMS
The aim of this systematic review was to locate, appraise, and synthe-
sise studies investigating the relationship between size at birth and
cognitive ability in late life.3 | MATERIALS AND METHODS
It was conducted according to the Cochrane guidelines for systematic
reviews of observational studies and adheres to the Preferred
Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA)
guidance.123.1 | Inclusion and exclusion criteria
Cross‐sectional or longitudinal studies examining the relationship
between any birth size parameter (birth weight, birth length, head
circumference, and ponderal index) and performance on any cognitive
function test in adults aged 50 years and above were eligible for
inclusion. Studies were excluded if they examined the association of
birth size with mental disorders (eg, depression) or physical health
(eg, frailty) without reporting measurements of cognitive performance
or were purely qualitative in nature.
3.2 | Identification and selection of studies
Searches were undertaken by three independent researchers (M.K., B.
D.U., and M.M.) in the following databases: MEDLINE, Embase,
PsychINFO, and CINAHL. Databases were searched from their inception
to February 2019. Two reviewers (M.K. and S.J.) independently screened
all the potential studies against the inclusion criteria. Disagreements
were resolved by discussion. The population search terms (both MeSH
terms and text words) for exposure included “birth weight, birth size, birth
length, ponderal index, growth in utero, fetal growth, fetal development,
fetal growth retardation, intrauterine growth, prenatal nutrition, and
fetal origins hypothesis,” and for outcome included “cognition, memory,
attention, recall, intelligence, brain function, and dementia.” Where
available, limits appropriate to participants (human studies), age (above
50 years), and study design (cohort studies, observational studies, and
longitudinal studies) were applied. No date or language restrictions
were applied. The search strategy from one of the engines (MEDLINE)
is provided as an appendix (Appendix A). Experts in the field were
contacted for any ongoing and unpublished studies. Authors were
contacted for additional information when indicated. Reference lists
of included studies were scanned for additional relevant publications.
Citation searches were also conducted on key papers. The International
Journal of Geriatric Psychiatry, Journal of Alzheimer's Disease and Demen-
tia, and Journal of Developmental Origins of Health and Disease were
manually searched from March 2015 to February 2019 (Figure 1).
3.3 | Data extraction and analyses
A data extraction form was created and piloted. Data were extracted
on all measurements of size at birth, scores on cognitive function tests
FIGURE 1 Flow diagram illustrating the process of selection of eligible studies for this systematic review
KRISHNA ET AL. 1141(both for individual domains and composite scores), and any other rel-
evant key data. The quality of eligible studies was evaluated using the
Strengthening the Reporting of OBservational Studies in Epidemiology
(STROBE) checklist.13 Two independent researchers (M.K. and S.J.)
undertook data extraction and quality assessment. Disagreements
were resolved by consensus.
If it was feasible to conduct a meta‐analysis, it was planned to
provide an estimate of combined effect size. If sufficient numbers of
eligible studies were retrieved, it was planned to evaluate publication
bias by a funnel plot analysis.4 | RESULTS
4.1 | Selection of studies
Selection process for this systematic review was conducted in accor-
dance with the PRISMA guidelines.12 Figure 1 outlines the results of
the search process. Of the 533 selected studies, 11 met the eligibility
criteria for this review.9-11,14-214.2 | Key characteristics
4.2.1 | Setting and design
The studies were published between 1996 and 2014 and included
community‐dwelling men and women who volunteered to participate.Two studies had a cross‐sectional design11,14 while others were longi-
tudinal follow‐ups of established cohorts.9,10,15-21 Of the 11 studies,
nine were cohort studies in which participants were matched to their
birth records. The other two were community‐based cohorts from the
United States. Set up for examining cardiovascular disorders and birth
weight was self‐reported by the participants (Table 1).4.2.2 | Demographics
The sample size ranged from 130 to 6875 and participants were aged
between 50 to 89 yrs. While Raikkonen et al included men only,
Erickson et al included women only.4.2.3 | Factors at birth
Birth weight was a universally available measurement of birth size
across all the studies. In two studies14,15 both from the USA, birth
weight was obtained by recall and non‐hospital records (such as family
diaries and birth certificates), and did not provide any other informa-
tion related to birth. All other studies were based on the birth weight
obtained from obstetric records. As a measurement of birth size, only
birth weight was available from obstetric records in Hyvarinen et al,
while Muller et al had an additional measurement of length at birth.
In addition to birth weight, length at birth, head circumference, and
gestational age were available from the maternity records in other
studies.9-11,16-18
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KRISHNA ET AL. 1143Parental occupation as an indicator of socioeconomic position at
birth was available from obstetric records in some studies,9,11,16,19
while occupation of the head of the household was available from
maternity records from de Rooij 2010 et al. Information about paren-
tal education at birth, an important determinant of growth and devel-
opment of the offspring, was not available in any of the studies.
4.2.4 | Cognitive outcomes
All studies examined memory and attention, while most studies (n = 9)
had a measure of verbal fluency as cognitive outcomes (Tables 1 and
2). Additional cognitive domains were examined in most of the studies.
They include: logical, verbal, and numerical reasoning in Martyn et al;
processing speed and executive function in Muller et al; general
intelligence and selective attention in de Rooij et al; processing
speed, selective attention, visuospatial performance, and motor skills
in Skogen et al; verbal, arithmetic and visual spatial reasoning in
Raikkoken et al; visuospatial tracking and attention in Erickson et al;
verbal and non‐verbal reasoning and executive function in Shenkin
et al 2009; intelligence in Zhang et al; reaction time and attention in
Hyvarinen et al; and intelligence in Gale et al. None of the studies
had cognitive impairment and dementia as outcomes, while, Hyvarinen
et al had a measure depressive symptoms.
4.2.5 | Confounding factors
The association of birth size with cognitive outcomes was adjusted for
a range of confounding factors in most of the studies (Table 2). They
include: gestational age, maternal age and parity, indicators of socio-
economic position at birth, attained educational level, social class of
participants, and cardiometabolic risk factors. However, these studies
do not provide information as to why these factors were thought to
be confounding and/or were important as covariates.
4.2.6 | Estimates of effect sizes and analyses
The strength of association of birth size parameters with cognitive
outcomes was examined and reported differently across studies
(Table 2). In addition, many of the eligible studies were relatively small;
from diverse population groups, both exposures and outcome
measures for cognitive function were multiple and heterogeneous
(Table 2). Therefore, it was not possible to conduct a metanalysis or
evaluate for publication bias.
4.3 | Quality of reporting and risk of bias
The quality of reporting of the studies as assessed by the STROBE
check list was good to excellent. At least 18 of the 22 items (range 18
to 22) from this checklist were reported (Appendix B). None of the
authors reported how the study size was derived. While some (n = 4)
did not report the effortsmade to address potential sources of bias, some
(n = 3) did not discuss the generalisability (external validity) of the study
results. Degree of overall bias as estimated from the STROBE check list
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1146 KRISHNA ET AL.for individual studies is provided in Table 2. The risk of bias was high
in Costa et al primarily because of relatively huge losses to follow‐up
and mutliple testing, and low in Zhang et al, Hyvarinen et al, and
Shenkin et al. The risk of bias was medium in other studies (Table 2).4.4 | Important studies that were excluded
1. Aroujo et al (2014) conducted cognitive assessments of 12 997
men and women aged 35 to 64 yrs from the Brazil Longitudinal
Study of Ageing, nearly half of them were aged above 50 years.22
Birth weight (self reported) was directly associated with cognitive
abilities in this study. However, the authors were unable to pro-
vide data specific to those aged 50 yrs and above.
2. Melrose et al (2013) examined the relationship between early life
environment and cognitive abilities in 333 men and women from
the UC Davis Diversity Ageing Cohort in the United States.23 This
study was excluded as authors did not specifically report the asso-
ciation of size at birth with cognitive abilities.
3. Richards et al (2001) reported the relationship between birth
weight and cognitive function in the British 1946 birth cohort.24
Participants were 43 yrs of age when examined and therefore
excluded from this review.
4. Dawes et al (2015) examined the effect of prenatal and childhood
development on hearing, vision, and cognition in the UK Biobank
Cohort.25 Participants were aged between 40 to 66 yrs, and birth
weight was self‐reported. Authors were contacted and they were
unable to provide data specific to those aged 50 yrs and above.5 | DISCUSSION
5.1 | Key findings
Studying early determinants and predictors of cognitive ageing has
been repeatedly identified as a research priority.26,27 The studies eval-
uated in this systematic review have contributed significantly to this
research and suggest that cognitive function in late life is influenced
by nutrition and environment in early life. A majority of the studies
(7 of the 11) included in this review indicate that intrauterine growth
restriction, crudely reflected in size at birth, is directly associated with
lower cognitive ability in late life, at least in high‐income country set-
tings. The overall effect sizes were small and there was insufficient
adjustment for important confounders in several studies. It was not
possible to compare and appraise the effect sizes of studies with each
other or conduct a meta‐analysis to derive a pooled effect size. This
was because the associations of different birth size parameters with
multiple cognitive outcomes for different domains have been reported
and the strength of associations has been reported differently.
The association of birth size with late life cognition was indepen-
dent of parental socioeconomic position at birth in most studies15-19
and was confounded by socioeconomic position at birth in one
study.11 Parental socioeconomic position at birth was not associatedwith cognitive function in late life in Shenkin et al, while this associa-
tion was not examined in the remaining studies.9,14,20,21
Across all the studies, adjusting for education attenuated the strength
of association of birth size with late life cognition. When reported
separately, higher level of attained education was directly associated
with higher scores for certain cognitive abilities. A possible mediating
or confounding effect of cardiometabolic disorders on the relationship
between size at birth and late life cognition was evaluated in three
studies included in this review: the direct association of size at birth
with late life cognition was independent of stroke and coronary heart
disease (CHD) in Raikkonen et al, diabetes and hypertension in Costa
et al, and diabetes and CHD in Hyvarinen et al. However, these studies
did not examine if smaller size at birth was associated with an increased
the risk of cardiometabolic disorders (as potential confounders).
The presence of a relationship between birth parameters and late
life cognitive ability does not necessarily imply a direct causal relation-
ship; birth parameters may merely reflect underlying influences. Resid-
ual confounding is a major possible reason for any false positive
associations. The mechanism of any influence of birth parameters on
cognitive ageing has not yet been established, and this may be a direct
or an indirect influence through cognitive reserve and cardiometabolic
pathways respectively.3,28 The studies in this review were not
designed to examine the DOHaD pathways of cognitive ageing. Such
a study would have examined the association of size at birth with cog-
nitive reserve and/or cardiometabolic risk factors in adult life and, in
turn, association of these with cognitive function in late life.
Cognitive decline is thought to begin as early as 40 years of age.29
Most studies in this review conducted baseline cognitive assessments
when participants were well above the age of 50, by which cognitive
decline may already be evident and observed associations (or a lack
of) in these studies may be due to a horse racing effect.30
While examining cognitive function in the studies included in this
review, cognitive decline may have been measured, and mostly the
papers were uninformative about this. However, cognitive decline was
specifically measured in four studies in this review. Of those that exam-
ined the relationship between birth size and cognitive decline, no asso-
ciation was reported in three studies,9,10,16 while in one study,17 men
with larger size at birth had slower rate of cognitive decline in late life.
Findings from this review also suggest that the relationship of
growth and development in early life is more likely with cognitive abil-
ities that are associated with the fronto‐temporal lobes of the brain
such as verbal fluency, attention, trail making, calculation, executive
functioning, and working memory. Of these, verbal fluency is regarded
as an index of crystallised intelligence, while others are generally con-
sidered as components of fluid intelligence. In fact, the verbal fluency
test is particularly sensitive to linguistic impairment and early mental
decline in older persons; it is also a sensitive indicator of damage to
the left lateral lobe.31,32
5.2 | Strengths and limitations of included studies
The studies that reported a positive association of size at birth with
late life cognitive ability generally included relatively well‐educated,
KRISHNA ET AL. 1147predominantly white, and middle‐class men and women from higher
income settings, which limits the generalisability of the findings
beyond these settings. Moreover, the estimates of the effect sizes
reported are at best modest. It is possible that the results are specific
to the cohorts under study (cohort bias). These individuals have seen
substantial changes in both prenatal and later health care.
None of the studies included in the review have information of the
entire eligible population to assess the degree of potential bias. The
studies used volunteers, who generally have higher cognitive ability
and social class than non‐volunteers.33 As all analyses were performed
within the study sample, unless the correlation between birth size and
cognitive ability differs between the volunteers and non volunteers, it
is unlikely that significant bias would have been introduced. Birth
weight in the United Kingdom, the United States, and Scandinavian
countries, where these studies were conducted, is among the highest
in the world, and they also have higher rates of literacy in comparison
to LMIC settings.26 It is reasonable to postulate that the effect size
would be different when studying the relationship between birth size
and late life cognition in LMIC populations with proportionately lower
birth size and literacy levels.
Attrition bias may have also affected results. Most studies do not
provide details about losses to follow‐up. When reported, those who
were lost to follow‐up had lower attained education level when com-
pared with those who were re‐examined, this bias may have influ-
enced findings towards non‐significant results.
As is common with longitudinal studies of older adults, partici-
pants who were lost to follow‐up in Shenkin et al and Raikkoken
et al had lower mean cognitive scores at baseline than those who
took part in the repeat testing. Such attrition may induce bias in the
estimates of cognitive change. These two studies examined decline
based on cognitive data only at two points in time. Random variation
or regression to the mean may account for some of the observed
changes in cognitive test scores and the results need to be treated
with caution.
Participant exclusion is also known to introduce bias. Although
most studies in this review excluded a minimal number of participants
(Table 1), one study15 excluded 36.6% (n = 3921) of participants
examined at the initial visit and such an extensive exclusion may limit
generalisability to the wider population. In two of the studies,14,15
both from the United States, birth weight was obtained by recall
and non‐hospital records like birth certificates and family diaries. A
problem with this is a possible greater inaccuracy of birth weight
recall in those with lower cognitive functioning. In fact, in Costa
et al, poorer performance in cognitive tests was observed in those
who recalled their birth weight when compared with those with avail-
able birth records. This was not examined in Erickson et al, as only a
small proportion of those recruited in this study had documented
birth weight.
When birth size data were extracted from routinely recorded
measurements from historic maternity records, it is possible that the
midwives rounded off the values to the nearest unit. The lack of asso-
ciation between cognitive performance and birth size measurements
in some of the studies in this review may be because of this inaccuracy.This was specifically examined in Martyn et al and there was evidence
of clumping of the data points suggesting rounding off values.
Five studies14-16,19,21 did not adjust the analyses for gestational
age, which reduces the specificity of birth weight as a measure of fetal
growth. This may have resulted in the lack of associations in some of
these studies. Most studies did not provide justifications for the
majority of adjustments (Table 2). Furthermore, one study15 adjusted
for a total of 21 different measures (not including gestational age),
which makes it difficult to assess how far participants represent the
general population. Some studies also did not provide any unadjusted
information, making it difficult to assess the role of covariates in the
reported effect (Table 2). Depression is related to both size at birth
and cognitive function,34 but the confounding effect of depression
on the association of size at birth with cognitive ability was measured
only in one study20 in this review.
In this review, most studies report associations of multiple param-
eters of birth size with multiple cognitive tests, measuring different
cognitive domains. While this allows for a comprehensive overview
of a variety of cognitive assessments, some significant associations
may have resulted from chance alone (risk of type I errors) and or
because of multiple testing. For example, in Erickson et al, birth weight
was associated with serial sevens test score (a single item from
MMSE), though there were no significant associations with 12 cogni-
tive function outcomes, including total MMSE score.
5.3 | Strengths and limitations of the review process
This review strictly adhered to the study protocol, which was devel-
oped prior to the formal search. The forward citation search and refer-
ence list search were conducted systematically. Several authors of
potentially eligible study were contacted for additional information.
All relevant studies appear to have been included in this review. There
were no restrictions on publication language, and full‐texts of all
potentially relevant articles were evaluated against the inclusion
criteria. However, the grey literature was not systematically searched
and this may have resulted in non‐identification of potentially relevant
studies. Furthermore, it is possible that there are unpublished studies
that were not available.
A limitation of this review was that only a small number of eligible
studies were retrieved, and it was not possible to conduct meta‐
analyses for summary statistics due to heterogeneity. There was con-
siderable heterogeneity across studies, and this is both strength and a
weakness. This was expected, given the range of different factors
known to contribute to both birth size and late life cognition, the dif-
ferent cognitive tests with their own scoring systems, and the range of
demographics across each study. Though most studies from this
review indicate that small size at birth is a risk factor for reduced cog-
nitive ability in late life, the clinical relevance of the findings is limited
as they do not include outcomes like cognitive impairment and
dementia. The generalisability of findings from this review is mostly
limited to higher income settings, and there is an urgent need for sim-
ilar studies in LMIC settings where the burden of both low birth
weight and dementia is highest.26
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research
In some studies in this review, relatively lower overall effect sizes and
a lack of substantial association between birth size and cognitive
function in late life may be a reflection of a diminished impact of early
factors, as other factors that mitigated these initial differences and
reduced or eliminated their influence in later adult life come into
play3,11; these may include later nutrition, education and occupation
status.3,28 Both birth weight and socioeconomic position in early life
are associated with cognitive function in childhood and adulthood,
although postnatal growth and development is thought to be more
important than prenatal factors.7,8 Cognition in late life is impacted
by a cumulative effect of nutrition, education, social, and family envi-
ronment in early and midlife.3 Therefore, there is definitely a need for
more research with a lifecourse approach while examining the
relationship between birth size and late life cognitive ability. The medi-
ating or confounding effect of childhood growth and development,
education, cardiometabolic risk factors, depression, and socioeco-
nomic position should be explored to better understand the lifecourse
pathways to cognitive ageing. Further, there is a need for studies
examining the underlying mechanisms (for eg, neuroimaging, genetic,
and epigenetic studies) linking early life nutrition to cognitive ageing.
Despite these limitations, the findings from this review may sup-
port the scientific rationale for improving maternal nutrition, best indi-
cated by the off‐spring birth size, which is known to persistent effect
on brain ageing. Recent improvements in the nutrition and education
of both mothers and children is likely to produce younger generations
with better cognitive health compared with the generation of older
adults examined in this review. There is evidence of such an improve-
ment in cognitive function and IQ scores across the generations,
mainly from high‐income countries. This is termed the Flynn effect.35
A comparison of scores from identical cognitive tests administered to
adults 10 to 30 years apart has shown an increase of about five to
nine IQ points per decade, and an increase of about five to 25 IQ
points over a generation.35 Further, a rise in intelligence scores of
about 12 IQ points over a period of 50 years or two IQ points per
decade has also been observed in the UK cohorts.36 The reasons for
such improvements in cognition and IQ across the generations are
not well understood. Possible mechanisms include improvements in
nutrition in early life and childhood, improvements in educational
standards and schooling, improvements in technology leading to easier
access to information, and perhaps increased complexity of the
environment. Thus, the existence of a Flynn effect, though not fully
proven, suggests that intelligence is not a fixed genetic attribute but
is modifiable by the environment.6 | CONCLUSIONS
Most studies in this review indicate that smaller size at birth is a risk
factor for lower cognitive function in late life, at least in higher income
countries. It was not possible to conduct meta‐analyses for summarystatistics due to clinical heterogeneity. While the aim of assessing
the association of birth size with cognitive ability in late life is to draw
conclusions about the relationship between the prenatal environment
and later cognitive outcomes, such definitive conclusions cannot be
drawn from birth size data alone. Future research should take a con-
sidered approach to covariates across the life course and explore path-
ways for cognitive ageing.
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APPENDIX A
Search strategy from MEDLINE.
1. MEDLINE; exp BIRTH WEIGHT/; 34390 results.
2. MEDLINE; (birth adj5 length).ti,ab; 3033 results.
3. MEDLINE; (birth adj5 circumference).ti,ab; 1149 results.
4. MEDLINE; "ponderal index".ti,ab; 938 results.
5. MEDLINE; exp INFANT, SMALL FOR GESTATIONAL AGE/;
5360 results.
6. MEDLINE; "small for gestational age".ti,ab; 6414 results.
7. MEDLINE; "foetal origins hypothesis".ti,ab; 15 results.
8. MEDLINE; "fetal origins hypothesis".ti,ab; 103 results.
9. MEDLINE; "growth in utero".ti,ab; 178 results.
10. MEDLINE; exp FETAL DEVELOPMENT/; 75682 results.
11. MEDLINE; "fetal growth".ti,ab; 10233 results.
12. MEDLINE; "foetal growth".ti,ab; 592 results.
13. MEDLINE; exp FETAL GROWTH RETARDATION/; 13101
results.
14. MEDLINE; "intrauterine growth".ti,ab; 10002 results.
15. MEDLINE; (prenatal adj5 undernutrition).ti,ab; 134 results.
16. MEDLINE; (birth adj5 size).ti,ab; 2958 results.
17. MEDLINE; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10
OR 11 OR 12 OR 13 OR 14 OR 15 OR 16; 121676 results.
18. MEDLINE; exp COGNITION/; 112890 results.
19. MEDLINE; exp MEMORY/; 102877 results.
20. MEDLINE; exp MENTAL RECALL/; 27549 results.
21. MEDLINE; exp ATTENTION/; 61050 results.
22. MEDLINE; cognition.ti,ab; 35514 results.
23. MEDLINE; memory.ti,ab; 163113 results.
1150 KRISHNA ET AL.24. MEDLINE; recall.ti,ab; 37487 results.
25. MEDLINE; attention.ti,ab; 251466 results.
26. MEDLINE; 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25;
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2‐3
Bias 9 Describe any efforts to address potential sources of bias. 3
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
3‐5
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
5‐6
(b) Describe any methods used to examine subgroups and
interactions.
no
(c) Explain how missing data were addressed. no
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
no
(e) Describe any sensitivity analyses. yes
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2
(b) Give reasons for non‐participation at each stage. 2
(c) Consider use of a flow diagram. no
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
3
(b) Indicate number of participants with missing data for each
variable of interest.
no
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount)
na
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
4‐6
Case‐control study. Report numbers in each exposure
category or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
4‐6
(b) Report category boundaries when continuous variables
were categorised.
4‐6
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
no
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
4‐6
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Item No Recommendation Page Number
Discussion 5‐6
Key results 18 Summarise key results with reference to study objectives. 6‐7
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
6‐7
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
6‐7
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
8
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
8
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1
Objectives 3 State specific objectives, including any prespecified
hypotheses.
1
Methods
Study design 4 Present key elements of study design early in the paper. 2
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
2‐3
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
4
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
4‐5
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
4‐5
Bias 9 Describe any efforts to address potential sources of bias. 4
Study size 10 Explain how the study size was arrived at. no
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Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
4‐5
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
4‐5
(b) Describe any methods used to examine subgroups and
interactions.
no
(c) Explain how missing data were addressed. no
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. 4‐5
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2‐4
(b) Give reasons for non‐participation at each stage. 2‐4
(c) Consider use of a flow diagram. no
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
2
(b) Indicate number of participants with missing data for each
variable of interest.
no
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
4
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
5
Case‐control study. Report numbers in each exposure
category, or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
4‐5
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
4‐5
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses
3
Discussion
Key results 18 Summarise key results with reference to study objectives. 3
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
4
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
4
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
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Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
5
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1‐2
Objectives 3 State specific objectives, including any prespecified
hypotheses.
1‐2
Methods
Study design 4 Present key elements of study design early in the paper. 1‐2
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants
2
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
2
Data sources/measurement 8* For each variable of interest, give sources of data and details of
methods of assessment (measurement). Describe comparability
of assessment methods if there is more than one group.
2
Bias 9 Describe any efforts to address potential sources of bias. 2
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
3
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
3‐4
(b) Describe any methods used to examine subgroups and
interactions.
no
(c) Explain how missing data were addressed. no
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. no
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Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2‐4
(b) Give reasons for non‐participation at each stage. no
(c) Consider use of a flow diagram. no
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
4
(b) Indicate number of participants with missing data for each
variable of interest.
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
4
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
Case‐control study. Report numbers in each exposure
category or summary measures of exposure.
4
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
5
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
5
Discussion
Key results 18 Summarise key results with reference to study objectives. 3
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
5
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
5
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
6
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1
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Objectives 3 State specific objectives, including any prespecified
hypotheses.
2
Methods
Study design 4 Present key elements of study design early in the paper. 2
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
2
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
2
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
2
Bias 9 Describe any efforts to address potential sources of bias. 2
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
2‐3
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
2‐3
(b) Describe any methods used to examine subgroups and
interactions.
3
(c) Explain how missing data were addressed. 3
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. no
Results 3
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2‐3
(b) Give reasons for non‐participation at each stage. no
(c) Consider use of a flow diagram. 3
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
3
(b) Indicate number of participants with missing data for each
variable of interest.
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(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
3
Case‐control study. Report numbers in each exposure
category, or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
4
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
4
Discussion
Key results 18 Summarise key results with reference to study objectives. 4
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
5
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
5
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
5
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1‐2
Objectives 3 State specific objectives, including any prespecified
hypotheses.
2
Methods
Study design 4 Present key elements of study design early in the paper. 2
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
2
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Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
2
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
2
Bias 9 Describe any efforts to address potential sources of bias. 2
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
2
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
2
(b) Describe any methods used to examine subgroups and
interactions.
no
(c) Explain how missing data were addressed. 2‐3
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. no
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2
(b) Give reasons for non‐participation at each stage. 2
(c) Consider use of a flow diagram.
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
2
(b) Indicate number of participants with missing data for each
variable of interest.
2
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
2‐3
Case‐control study. Report numbers in each exposure
category or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
3‐4
(b) Report category boundaries when continuous variables
were categorised.
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(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
3‐4
Discussion
Key results 18 Summarise key results with reference to study objectives. 4
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
5
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
5
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
6
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
6
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1
Objectives 3 State specific objectives, including any prespecified
hypotheses.
1
Methods
Study design 4 Present key elements of study design early in the paper. 1
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
1‐2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
2
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
2
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
2
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Bias 9 Describe any efforts to address potential sources of bias. 2
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
2
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
2
(b) Describe any methods used to examine subgroups and
interactions.
no
(c) Explain how missing data were addressed. 2
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. no
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
1‐2
(b) Give reasons for non‐participation at each stage. 1‐2
(c) Consider use of a flow diagram. no
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
2
(b) Indicate number of participants with missing data for each
variable of interest.
2
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
2‐3
Case‐control study. Report numbers in each exposure
category or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
2‐3
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
2‐3
Discussion
Key results 18 Summarise key results with reference to study objectives. 2
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
2
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
3
(Continues)
KRISHNA ET AL. 1165
(Continued)
Item No Recommendation Page Number
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
4
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1
Objectives 3 State specific objectives, including any prespecified
hypotheses.
2
Methods
Study design 4 Present key elements of study design early in the paper. 2
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
3
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
3
Bias 9 Describe any efforts to address potential sources of bias. 3
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
3‐4
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
3‐4
(b) Describe any methods used to examine subgroups and
interactions.
3‐4
(c) Explain how missing data were addressed. 3‐4
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
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Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
(e) Describe any sensitivity analyses. no
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
2‐3
(b) Give reasons for non‐participation at each stage. 2‐3
(c) Consider use of a flow diagram. no
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
2‐3
(b) Indicate number of participants with missing data for each
variable of interest.
2‐3
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
3‐4
Case‐control study. Report numbers in each exposure
category or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
4‐5
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
4‐5
Discussion
Key results 18 Summarise key results with reference to study objectives. 6
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
6
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
6‐7
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
7
Item No Recommendation Page Number
Title and abstract 1 (a) Indicate the study's design with a commonly used term in
the title or the abstract.
1
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found.
1
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Item No Recommendation Page Number
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported.
1, 2
Objectives 3 State specific objectives, including any prespecified
hypotheses.
2, 3
Methods
Study design 4 Present key elements of study design early in the paper. 2, 3
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow‐up, and data
collection.
2, 3
Participants 6 (a) Cohort study. Give the eligibility criteria and the sources
and methods of selection of participants. Describe
methods of follow‐up.
Case‐control study. Give the eligibility criteria and the sources
and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls.
Cross‐sectional study. Give the eligibility criteria and the
sources and methods of selection of participants.
2, 3, 4
(b) Cohort study. For matched studies, give matching criteria
and number of exposed and unexposed.
Case‐control study. For matched studies, give matching
criteria and the number of controls per case.
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.
3, 4
Data sources/measurement 8* For each variable of interest, give sources of data and details
of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group.
3, 4
Bias 9 Describe any efforts to address potential sources of bias. 3, 4
Study size 10 Explain how the study size was arrived at. no
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why.
6, 7
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding.
6, 7
(b) Describe any methods used to examine subgroups and
interactions.
6, 7
(c) Explain how missing data were addressed.
(d) Cohort study. If applicable, explain how loss to follow‐up
was addressed.
Case‐control study. If applicable, explain how matching of
cases and controls was addressed.
Cross‐sectional study. If applicable, describe analytical
methods taking account of sampling strategy.
3
(e) Describe any sensitivity analyses. no
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg,
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow‐up, and analysed.
3, 4
(b) Give reasons for non‐participation at each stage. 3, 4
(c) Consider use of a flow diagram. 3
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Descriptive data 14* (a) Give characteristics of study participants (eg, demographic,
clinical, and social) and information on exposures and
potential confounders.
6
(b) Indicate number of participants with missing data for each
variable of interest.
no
(c) Cohort study. Summarise follow‐up time (eg, average and
total amount).
3
Outcome data 15* Cohort study. Report numbers of outcome events or summary
measures over time.
3
Case‐control study—Report numbers in each exposure
category or summary measures of exposure.
Cross‐sectional study. Report numbers of outcome events or
summary measures.
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder‐
adjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included.
7‐9
(b) Report category boundaries when continuous variables
were categorised.
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period.
Other analyses 17 Report other analyses done—eg, analyses of subgroups and
interactions and sensitivity analyses.
7‐9
Discussion
Key results 18 Summarise key results with reference to study objectives. 5‐11
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
10
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
10‐11
Generalisability 21 Discuss the generalisability (external validity) of the study
results.
no
Other information
Funding 22 Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based.
11
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